Mitochondrial dysfunction, depression, and SS-31
At a glance
What the evidence says
Mitochondrial dysfunction is increasingly supported as one biological contributor to major depressive disorder, particularly through impaired oxidative phosphorylation, altered electron transport chain activity, oxidative stress, neuroinflammation, calcium dysregulation, impaired mitophagy, apoptosis, and reduced neuroplasticity.
The strongest human evidence remains associative rather than causal. Peripheral respiration studies, mtDNA analyses, immune-metabolic signals, patient-derived fibroblasts, iPSC-derived neural models, postmortem findings, and treatment-response biomarker work all point in the same general direction, but heterogeneity is substantial and there is no clinically validated mitochondrial diagnostic test for depression.
SS-31, also known as elamipretide, is biologically plausible for mitochondrial and inflammatory subtypes of depression because it targets cardiolipin-centered mitochondrial membrane dysfunction. Even so, direct depression evidence is limited, with the clearest signal coming from preclinical animal work rather than human psychiatric trials.
Depression link
Moderate-to-strong evidence supports mitochondrial involvement in a subset of MDD phenotypes, especially those marked by inflammatory or metabolic stress.
SS-31 rationale
Mechanistic data suggest improved cristae integrity, reduced ROS burden, preservation of ATP production, and modulation of apoptosis-related signaling.
Bottom line
SS-31 fits the biology well, but it should still be treated as plausible and unproven for depression until human trials exist.
Core biological pathways
| Pathway | Data supporting involvement in depression | Interpretation |
|---|---|---|
| Impaired OXPHOS and electron transport | Reviews summarize reduced ETC expression and activity, altered complex I/II/IV function, lower oxygen consumption, mitochondrial depolarization, altered ATP-related metabolites, and mitochondrial damage across models and human samples. | Energy-production impairment may help explain fatigue, psychomotor slowing, cognitive symptoms, reduced stress resilience, and impaired synaptic plasticity. |
| Oxidative stress | Depression studies report increased ROS-related injury, lipid peroxidation, mtDNA oxidative damage, and reduced antioxidant defenses such as glutathione and SOD. | Oxidative stress is one of the clearest bridges linking mitochondrial dysfunction to inflammation, apoptosis, and loss of plasticity. |
| Neuroinflammation and mtDNA danger signaling | Mitochondrial damage can release mtDNA and activate inflammatory pathways such as NF-kB, TLR9, and NLRP3. Meta-analytic data suggest higher mtDNA levels overall in depression, though with high heterogeneity. | This supports a mitochondria-inflammation loop, but sample type and study design matter heavily. |
| Impaired mitophagy | Depression literature implicates PINK1/Parkin, BNIP3/NIX, sirtuins, lysosomal function, and NLRP3-linked inflammation in defective mitochondrial quality control. | Mitophagy failure may be a maintenance problem that allows damaged mitochondria to accumulate and amplify inflammatory stress. |
| Calcium dysregulation and apoptosis | Reviews connect mitochondrial calcium overload with depolarization, permeability transition, cytochrome c release, caspase activation, and apoptosis. | This pathway links excitotoxic stress, neuroplasticity loss, and mitochondrial injury. |
| Neuroplasticity and BDNF signaling | Mitochondrial dysfunction affects ATP availability, ROS signaling, dendritic remodeling, synaptic function, and hippocampal neurogenesis. | These findings connect cellular energy deficits to symptoms and treatment response, although mechanisms likely vary by brain region and subtype. |
Human and cellular data
| Evidence type | Key findings | Strengths and limitations |
|---|---|---|
| mtDNA meta-analysis | A 2023 systematic review/meta-analysis found higher mtDNA levels in depression versus controls, with a standardized mean difference of 0.42 and substantial heterogeneity. | Useful quantitative synthesis, but results varied by tissue, specimen type, geography, and detection method, and most studies were cross-sectional. |
| PBMC respiration | A case-control study found lower routine respiration, uncoupled respiration, ATP turnover-related respiration, spare respiratory capacity, and coupling efficiency in PBMCs from women with major depression. | Provides direct functional respiration data, though medicated status, smoking, and BMI may confound interpretation. |
| T-cell immunometabolism | An unmedicated MDD study reported systemic dyslipidemia plus reduced respiratory and glycolytic capacity in T cells, with increased CPT1a expression. | Important for showing signal in unmedicated patients, but still peripheral rather than direct brain evidence. |
| Patient-derived fibroblasts | MDD-derived fibroblasts showed lower basal and maximal respiration, reduced ATP-related oxygen consumption, lower ATP levels, and hyperpolarized mitochondrial membrane potential. | These models may reflect intrinsic patient bioenergetic differences, but fibroblasts are not neurons. |
| iPSC-derived neural cells | Neural progenitor cells from MDD patients showed lower maximal respiration, altered basal calcium, and smaller soma size; derived neurons also differed electrophysiologically. | More CNS-relevant than blood measures, though sample sizes remain small. |
| Treatment-response biomarkers | Blood mitochondrial respiratory-chain markers did not cleanly separate MDD from controls overall, but did distinguish SSRI responders from nonresponders in one study. | Suggests mitochondrial measurements may be more useful for stratification or response prediction than diagnosis. |
MDD is biologically heterogeneous, and mitochondrial dysfunction is more plausibly a contributor in a subset of patients than a universal root cause. Future clinical use would likely depend on multi-marker panels rather than any single mitochondrial assay.
How SS-31 targets mitochondrial dysfunction
SS-31, also called elamipretide, MTP-131, or Bendavia, is a synthetic amphipathic tetrapeptide designed to localize to the inner mitochondrial membrane and interact with cardiolipin-rich regions.
Its proposed effects include stabilization of cristae architecture, improved electron transport efficiency, reduced reactive oxygen species, preservation of ATP production, inhibition of cytochrome c/cardiolipin peroxidase activity, and reduced swelling and apoptosis signaling.
| SS-31 action | Data | Why it matters |
|---|---|---|
| Binds cardiolipin | SS-31 binds cardiolipin through electrostatic interaction with phosphate heads and hydrophobic interaction with acyl chains. | Cardiolipin organizes cristae, respiratory supercomplexes, cytochrome c interactions, and ATP synthase function. |
| Protects cytochrome c/cardiolipin function | The SS-31/cardiolipin complex inhibits cardiolipin-induced cytochrome c peroxidase activity and preserves cytochrome c configuration. | This may reduce cardiolipin peroxidation, cytochrome c release, and mitochondrial apoptosis signaling. |
| Preserves cristae and ultrastructure | In renal ischemia-reperfusion models, SS-31 protected cristae membranes, reduced swelling, and accelerated ATP recovery. | Cristae integrity is central to efficient OXPHOS and ATP synthesis. |
| Interacts with OXPHOS and metabolic proteins | Cross-linking and mass spectrometry work identified multiple SS-31-interacting mitochondrial proteins, including complex III, complex IV, ATP synthase, ANT, creatine kinase, and 2-oxoglutarate metabolism enzymes. | This supports a mechanism beyond generic antioxidant activity and suggests optimization of the protein-lipid environment of energy metabolism. |
| Improves morphology, dynamics, and quality control | Long-term SS-31 improved cristae density, reduced vacuolated mitochondria, lowered pro-fission signaling, and reduced p62 accumulation in Barth syndrome models. | These effects may be relevant if depression phenotypes include impaired mitophagy or dysfunctional mitochondrial dynamics. |
| Reduces ROS, inflammation, and apoptosis in CNS injury models | Preclinical CNS injury studies show lower mitochondrial ROS and MDA, restoration of SOD, reduced Bax/caspase signaling, and improved bioenergetic or functional readouts. | These pathways overlap strongly with stress, inflammation, and oxidative mechanisms implicated in mood disorders. |
Clinical data relevant to mitochondrial dysfunction
| Indication/study | Design and dose | Main outcomes | Interpretation |
|---|---|---|---|
| Primary mitochondrial myopathy, phase I/II MMPOWER | 36 adults; IV elamipretide for 5 days at ascending doses up to 0.25 mg/kg/h. | Highest dose showed a mean 64.5 m increase in 6MWT at day 5 versus 20.4 m with placebo, with no major safety signal. | Early, short-duration signal for exercise performance in mitochondrial disease. |
| Primary mitochondrial myopathy, MMPOWER-2 | 30 adults; randomized crossover; 40 mg/day subcutaneous elamipretide for 4 weeks versus placebo. | The primary 6MWT difference was 19.8 m and not statistically significant, though several fatigue-related patient-reported outcomes improved nominally. | Suggestive symptom signal, but not a definitive efficacy study. |
| Primary mitochondrial myopathy, MMPOWER-3 | 218 participants; 40 mg/day subcutaneous elamipretide for 24 weeks versus placebo. | The trial did not meet primary endpoints overall; a post hoc nDNA subgroup showed a positive 6MWT signal. | Mechanistic rationale did not translate to broad phase 3 efficacy. |
| Barth syndrome, TAZPOWER | Randomized crossover plus open-label extension using 40 mg/day. | The randomized phase did not meet primary endpoints, while longer open-label follow-up suggested functional improvements. | Supports a duration-sensitive signal in a cardiolipin-related disease, but open-label data are more vulnerable to bias. |
| Heart failure, PROGRESS-HF | 71 HFrEF patients; 4 mg or 40 mg daily for 28 days. | Elamipretide was well tolerated but did not improve major LV remodeling or ejection fraction endpoints over 4 weeks. | Not all mitochondrial-stress conditions translate into short-term clinical benefit. |
Across trials, elamipretide has generally been reported as well tolerated, with injection-site reactions, headache, dizziness, nausea, abdominal pain, and fatigue commonly described as mild or transient adverse events.
Data on SS-31 and depression
The most directly relevant depression-model evidence identified is a chronic unpredictable mild stress mouse study in which SS-31 served as a mitochondria-targeted antioxidant comparator.
In that study, daily SS-31 during the 5-week stress procedure improved depressive-like behaviors, including reduced forced-swim immobility, increased rearing in the open field, and greater open-arm time in the elevated plus maze without changing overall locomotion.
The same work reported reversal of hippocampal NLRP3, cleaved caspase-1, cleaved IL-1beta, IL-1beta, IL-6, and iNOS changes, linking SS-31 to a depression-relevant mitochondrial oxidative stress to inflammasome pathway.
This does not establish SS-31 as a clinical antidepressant. The study was in mice, SS-31 was given during stress exposure rather than after diagnosed human MDD, and the paper’s main therapeutic focus was catalpol rather than SS-31 as a standalone psychiatric intervention.
| CNS model | SS-31 findings | Relevance to depression |
|---|---|---|
| LPS-induced hippocampal inflammation and memory impairment | SS-31 reduced mitochondrial membrane potential loss, ATP reduction, ROS, MDA, IL-6, TNF-alpha, apoptosis, and dendritic spine loss while restoring BDNF/TrkB signaling and synaptic proteins. | Strongly relevant to depression biology, but the measured outcomes were cognitive rather than depressive-like behavior. |
| Traumatic brain injury | SS-31 reduced mitochondrial ROS and oxidative injury, restored mitochondrial cytochrome c and SOD, reduced apoptosis markers, increased SIRT1/PGC-1alpha signaling, and improved function. | TBI is not depression, but it demonstrates CNS mitochondrial rescue in oxidative and inflammatory injury states. |
| Aged neurovascular dysfunction | SS-31 reduced mtROS, improved respiration in cerebromicrovascular endothelial cells, restored neurovascular coupling, and improved spatial working memory. | Relevant to brain energy delivery and cognitive symptoms, though not an antidepressant model. |
Why SS-31 is plausible but unproven
The strongest mechanistic bridge is the mitochondrial oxidative stress to NLRP3 and neuroinflammation axis.
SS-31 maps onto multiple abnormalities implicated in depression: impaired OXPHOS, excess ROS, cardiolipin and cytochrome c dysfunction, apoptosis, inflammasome activation, inflammatory cytokine signaling, reduced BDNF-linked plasticity, impaired mitochondrial biogenesis, and disrupted mitophagy and dynamics.
A second bridge is bioenergetics and neuroplasticity. Depression is associated with lower ATP-linked respiratory capacity and altered plasticity pathways, while SS-31 has improved ATP, membrane potential, BDNF/TrkB signaling, synaptic proteins, and dendritic spine metrics in relevant CNS models.
The key weakness is translational distance: improving mitochondrial endpoints does not necessarily improve depression, and human elamipretide programs in other diseases have already shown that strong mechanism does not guarantee positive clinical endpoints.
Evidence gaps and research directions
| Question | Current evidence grade | Practical readout |
|---|---|---|
| Is mitochondrial dysfunction associated with depression? | Moderate to strong for association; not yet definitive for causality. | Multiple human, cellular, and animal lines converge, but confounding and heterogeneity remain substantial. |
| Does SS-31 improve mitochondrial dysfunction? | Strong preclinical evidence; mixed but meaningful clinical evidence in selected mitochondrial disorders. | Mechanistic support is robust, but clinical benefit appears indication-, endpoint-, genotype-, and duration-dependent. |
| Does SS-31 improve depression? | Limited preclinical evidence; no identified human depression trial. | One CUMS mouse study supports antidepressant-like effects and reduced NLRP3-linked inflammation, but clinical translation is unproven. |
Useful next steps would include randomized controlled trials in MDD or treatment-resistant depression, ideally enriched for mitochondrial or inflammatory abnormalities such as low PBMC respiration, elevated mtDNA or cf-mtDNA, high inflammatory markers, metabolic dysfunction, or fatigue-dominant phenotypes.
High-quality psychiatric trials should pair symptom scales with mitochondrial respiration endpoints, ATP-linked respiration, mtDNA metrics, cytokines, oxidative-stress markers, metabolomics, and ideally neuroimaging or magnetic resonance spectroscopy readouts of brain energetics.
